IP Library › Granted Patent US 12,410,394
Granted Patent B2
US 12,410,394 · App. 18/093,860 · Granted Sep 9, 2025

Composition comprising nicotinamide mononucleotide and leucomethylene blue

Inventor: Joseph Chalifoux (Nashua, NH)
Assignee: Athergen, Inc.
C12N5/0018C12N5/0607C12N15/86C12N2500/40C12N2501/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,394
App. No.
18/093,860
Granted
Sep 9, 2025
Kind
B2
Abstract

A cell reprogramming composition and method wherein the composition includes a base molecule, β-nicotinamide mononucleotide, trichostatin A and zwitterionic liposomes and wherein the method includes receiving a cell and reprogramming agents, wherein the reprogramming agents comprise Oct-4, Sox 2 and Klf4, to reprogram the cell to an embryonic state.

Claims (14)

1. A composition comprising:

a base molecule;

a combination of nicotinamide mononucleotide and leucomethylene blue, wherein the combination comprises aqueous leucomethylene blue-nicotinamide mononucleotide version 1 (AqLNMNol);

a combination of trichostatin A and aqueous leucomethylene blue-nicotinamide mononucleotide version 1, wherein the combination comprises aqueous leucomethylene blue-nicotinamide mononucleotide version 2 (AqLNMNo2); and

zwitterionic liposomes.

2. The composition of claim 1 , wherein the base molecule comprises partially reduced methylene blue.

3. The composition of claim 1 , wherein the base molecule and the (3-nicotinamide mononucleotide are bonded together by chemical bonds.

4. The composition of claim 1 , wherein the composition further comprises an octamer activating compound 1 (OAC1).

5. The composition of claim 1 , wherein the trichostatin A is combined with the AqLNMNol by way of a hydroxyl group.

6. The composition of claim 2 , wherein AqLNMNol the partially reduced methylene blue, and AqLNMNo2 comprises a synthetic molecule.

7. The composition of claim 1 , wherein the composition further comprises vorinostat, wherein the vorinostat is combined with the AqLNMNol by way of a hydroxyl group.

8. The composition of claim 1 , wherein the zwitterionic liposomes are hydrated and extruded.

9. The composition of claim 1 , wherein the composition is configured to be suitable for oral administration.

10. The composition of claim 1 , wherein the zwitterionic liposomes comprise amino acids.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2025
From: CHALIFOUX, JOSEPH
To: ATHERGEN, INC.
Reel/Frame 070414/0710 →
Continuity (1)
Related Publication 20240228949A1 · Jul 11, 2024
References Cited (17)
US 11324764B2 · Dischler · 2022 [cited by applicant]
US 11344558B2 · Wischik · 2022 [cited by applicant]
US 20110256175A1 · Hope · 2011 [cited by examiner]
US 20150320706A1 · Imbimbo · 2015 [cited by applicant]
US 20180021553A1 · Wang · 2018 [cited by examiner]
US 20180216076A1 · Hebrok · 2018 [cited by examiner]
US 20210244665A1 · Fisher · 2021 [cited by examiner]
WO WO2017082294A1 · 2017 [cited by examiner]
WO 2021001326A1 · 2021 [cited by applicant]
WO WO2022184825A1 · 2022 [cited by examiner]
Yap et al. “Deriving Insulin-Producing Cells from Trans-differentiating Adipose-Derived Mesenchymal Stem Cells.” Diabetes. vol. 66. 1701 N Beauregard St, Alexandria, VA 22311-1717 USA: Amer Diabetes Assoc, 2017. (Year: … [cited by examiner]
Yoshino et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. Jun. 11, 2021;372(6547):1224-1229. (Year: 2021). [cited by examiner]
Galagan et al. “Reversible photoreduction of methylene blue in acrylate media containing benzyl dimethyl ketal.” Journal of Photochemistry and Photobiology A: Chemistry 195.2-3 (2008): 378-383. (Year: 2008). [cited by examiner]
Collas et al. “On the way to reprogramming cells to pluripotency using cell-free extracts.” Reprod Biomed Online. Jun. 2006;12(6):762-70. (Year: 2006). [cited by examiner]
Kelaini et al. “Direct reprogramming of adult cells: avoiding the pluripotent state.” Stem Cells Cloning. 2014; 7: 19-29. (Year: 2014). [cited by examiner]
Qin et al. “Small molecules for reprogramming and transdifferentiation.” Cellular and Molecular Life Sciences vol. 74, pp. 3553-3575 (2017) (Year: 2017). [cited by examiner]
Hao et al. “Direct induction of functional neuronal cells from fibroblast-like cells derived from adult human retina.” Stem Cell Res. Aug. 2017;23:61-72. (Year: 2017). [cited by examiner]